announcements & circulars-凯发88
english
凯发88-凯发vip-娱乐凯发app下载
中文繁体
company
overview
board of directors
scientific advisory board
partnering
core competence
technology
bispecific
mix-mab
biologics manufacturing
publications
pipeline
overview
envafolimab(kn035)
kn046
kn026
kn026 kn046
kn019
investors
information disclosure
corporate governance
stock information
ir contacts
email subscription
news
press release
media report
career
corporate culture
job opportunities
contact us
company
overview
board of directors
scientific advisory board
partnering
core competence
technology
bispecific
mix-mab
biologics manufacturing
publications
pipeline
overview
envafolimab(kn035)
kn046
kn026
kn026 kn046
kn019
investors
information disclosure
corporate governance
stock information
ir contacts
email subscription
news
press release
media report
career
corporate culture
job opportunities
contact us
english
凯发88-凯发vip-娱乐凯发app下载
中文繁体
investors
information disclosure
listing documents
financial reports
announcements & circulars
company presentation
corporate governance
stock information
ir contacts
email subscription
announcements & circulars
the announcement begins in december 2019
2020 environmental, social and governance report
2021-05-20
voluntary announcement - research results on kn046 and kn026 for presentation at 2021 asco annual meeting
2021-05-20
voluntary announcement - abstracts and e-posters of research updates on kn046 and kn026 for presentation at 2021 asco annual meeting
2021-05-07
monthly return of equity issuer on movements in securities for the month ended 30 april 2021
2021-05-07
notice of annual general meeting
2021-04-27
form of proxy for use at the annual general meeting to be held on friday, june 11, 2021
2021-04-27
(1) proposed granting of general mandates to repurchase shares and to issue new shares; (2) proposed re-election of the retiring directors; (3) proposed re-appointment of auditors; and (4) notice of annual general meeting
2021-04-27
grant of share options
2021-04-23
voluntary announcement - preliminary safety tolerability and efficacy results of kn046 in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer released for e-poster presentation at 2021 aacr annual meeting
2021-04-12
monthly return of equity issuer on movements in securities for the month ended 31 march 2021
2021-04-09
1
2
3
4
5
6
7
prev
4/11
next
网站地图